Daily Morning Note – 30 April 2020
Asian equity markets were poised to gain on Thursday, tracking Wall Street’s rally after positive trial results of an experimental COVID-19 treatment, a U.S. Federal Reserve pledge to shore up the economy and a jump in oil prices. On Wall Street, the Dow Jones Industrial Average .DJI rose 2.21%, the S&P 500 .SPX gained 2.66% and the Nasdaq Composite .IXIC added 3.57%. U.S. West Texas Intermediate (WTI) crude futures settled at $15.06 a barrel, jumping $2.72, or 22%. Brent crude futures settled at $22.54 a barrel, up $2.08, or 10.2%. The Fed left key interest rates near zero while Chair Jerome Powell warned the economy would drop at an “unprecedented rate” in the current quarter.
SINGTEL and a joint venture between StarHub and M1 have provisionally clinched Singapore’s first nationwide 5G operating licences, the Infocomm Media Development Authority (IMDA) announced on Wednesday.
DBS Group Holdings set aside S$1.09 billion to cover the impact of the coronavirus pandemic as South-east Asia’s biggest lender reported a 29 per cent fall in first-quarter profit to the lowest in 2.5 years.
UMS Holdings has resumed normal operations at its factory in Penang, following the Malaysian government’s green light, the company announced in a bourse filing on Wednesday.
CAPITALAND Commercial Trust (CCT) posted a 25 per cent fall in Distribution Per Unit (DPU) to 1.65 cents for the first quarter ended March, due to its retention of taxable distributable income and its decision to withhold distribution of tax-exempt income “as a matter of prudence” amid the Covid-19 outbreak.
THE net profit of mainboard-listed Keppel Corp fell 20.9 per cent to S$160.5 million for the first quarter ended March, mainly on the absence of the divestment of its 70 per cent stake in Vietnam’s Dong Nai Waterfront City a year ago.
IX BIOPHARMA saw its shares surge as much as 22.4 per cent when the market opened following news of the company formalising a supply agreement with Cannatrek Medical Pty Ltd to supply Xativa in Australia. The pharmaceutical company’s shares rose 0.55 Singapore cent to 30 cents as at 9.01am on Wednesday, compared with a Tuesday closing price of 24.5 cents.
Source: SGX Masnet, The Business Times, Bloomberg, Channel NewsAsia, Reuters, PSR
Sheng Siong Group Ltd – Stellar quarter should continue
ACCUMULATE (Maintained); TP S$1.58, Last close: S$1.46
– 1Q20 revenue and earnings beat our estimates. 1Q20 PATMI surged 48% YoY to S$29mn
– 1Q20 benefited from a general improvement in consumer sentiment during the festive period and pantry loading when DORSCON was raised to orange.
– The positive sales momentum should continue into 2Q20 due to increased dining at home by households following the circuit breaker that begun in Singapore on 7 April and likely to end on 1 June.
– We are raising our FY20e PATMI by 12% as we increased our revenue forecast by S$100mn. Our revised FY20e earnings has even exceeded our previous FY21e forecast. We think the outbreak generated incremental S$50mn in revenue in for 1Q20. with an additional S$50mn for 2Q20e. Our ACCUMULATE recommendation is maintained and target price raised to S$1.58 (previously S$1.41). We also expect dividends in FY20e to be raised by 26% to 4.5 cents, as we use 70% dividend payout ratio as a guide.
HK Reports – Read up on our Hong Kong reports here
Webinar Of The Week
Date: 27 April 2020
|The information contained in this email and/or its attachment(s) is provided to you for information only and is not intended to or nor will it create/induce the creation of any binding legal relations. The information or opinions provided in this email do not constitute an investment advice, an offer or solicitation to subscribe for, purchase or sell the e investment product(s) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of this information. Investments are subject to investment risks including possible loss of the principal amount invested. The value of the product and the income from them may fall as well as rise. You may wish to seek advice from an independent financial adviser before making a commitment to purchase or investing in the investment product(s) mentioned herein. In the event that you choose not to do so, you should consider whether the investment product(s) mentioned herein is suitable for you. PhillipCapital and any of its members will not, in any event, be liable to you for any direct/indirect or any other damages of any kind arising from or in connection with your reliance on any information in and/or materials attached to this email. The information and/or materials provided 揳s is?without warranty of any kind, either express or implied. In particular, no warranty regarding accuracy or fitness for a purpose is given in connection with such information and materials.|
|This e-mail and its attachment(s) may contain privileged or confidential information, which is intended only for the use of the recipient(s) named above. If you have received this message in error, please notify the sender immediately and delete all copies of it. If you are not the intended recipient, you must not read, use, copy, store, disseminate and/or disclose to any person this email and any of its attachment(s). PhillipCapital and its members will not accept legal responsibility for the contents of this message. Thank you for your cooperation.|